Food and Drug Administration (FDA)2019-09-252019-09-252014-12-222014-01http://hdl.handle.net/20.500.12424/216126"This draft guidance describes FDA’s current thinking on what the Agency considers to be interactive promotional media and outlines the considerations taken into account in determining if product communications using interactive technologies are subject to FDA’s postmarketing submission requirements. Furthermore, this draft guidance provides FDA’s recommendations for how firms can fulfill the regulatory requirement to 31 submit postmarketing promotional materials to the FDA in a practical manner to address the potential volume of real time information that is continuously posted and shared through various interactive promotional media platforms."engWith permission of the license/copyright holderCode of ethicscode of conductFood and Drug Administration (FDA)public healthpromotionshuman prescriptionsanimal prescriptionsCultural ethicsMedia/communication/information ethicsBioethicsMedical ethicsPreprint